- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07625059
Stanford University Microbiome Bank (SUMB)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Eligible participants will undergo comprehensive baseline screening including physical examination, infectious disease testing, and health history assessment. Those who qualify will enter an active donation period of up to 12 months, during which they will provide stool samples at a frequency ranging from once per month to once per week, depending on their availability.
In addition to stool collection, participants will provide biospecimens including blood draws (for infectious disease and metabolic monitoring), saliva samples, and small intestinal fluid samples collected using an ingestible capsule device (CapScan). The CapScan capsule is swallowed by the participant, collects intestinal fluid as it passes through the small intestine, and is retrieved from stool and returned to the research team for analysis.
This biobank will serve as infrastructure for ongoing microbiome research, providing rigorously screened and comprehensively characterized biospecimens to advance understanding of the gut microbiome's role in health and disease, and to support development of safe and effective microbiota-based therapies.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Roujheen Sabetan, MPH
- Numéro de téléphone: 650-498-8188
- E-mail: rsabetan@stanford.edu
Lieux d'étude
-
-
California
-
Palo Alto, California, États-Unis, 94305
- Stanford University
-
Contact:
- Roujheen Sabetan, MPH
- Numéro de téléphone: 650-498-8188
- E-mail: rsabetan@stanford.edu
-
Chercheur principal:
- Sean Spencer, MD, PHD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Any person aged 18-80 years of age, inclusive at the time of signing the consent
- In good general health as evidenced by medical history
- Ability to travel to donation facility on a weekly basis
- Residence within 5 miles of Stanford Campus
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation
- Capable of providing signed informed consent.
Exclusion Criteria:
- Inflammatory bowel disease
- Enteric infections
- Previous infection with Clostridium difficile
- History of gastrointestinal surgery: Participants with gastrointestinal surgeries below the pylorus will be excluded from this protocol, including participants with a history of colectomy, segmental colonic resection, and small bowel resections.
- Documented severe gastroparesis
- Active intestinal obstruction
- Dysphagia (oropharyngeal, esophageal, functional or neuromuscular)
- History or current malignancy diagnosis
- History of recurrent aspiration episodes
- Any conditions associated with a high risk of bleeding, including but not limited to coagulopathy/bleeding disorder, severe liver disease, active or recent GI bleeding, or recent abdominal or other GI surgery
- Active diagnosis of major depressive disorder
- Active diagnosis of major anxiety disorder
- Severe immunodeficiency, inherited or acquired (e.g., Human immunodeficiency virus, active chemotherapy or immunosuppressive medications [including steroids, biologic therapy, or bone marrow suppressive agents], or radiation therapy)
- BMI of less than 18 or BMI greater than 30
- Record of eating disorders
- Active use of GLP-1 inhibitors
- Diagnosis of Human immunodeficiency virus infection; Hepatitis A, B, C & E; Epstein Bar Virus; parasitic infections; Syphilis
- Pregnancy & lactation
- Active drug, or alcohol use disorder
- Tobacco, marijuana and e-cigarette use
- Any other significant medical condition that could confound or interfere with evaluation of safety or tolerability or prevent compliance with the study protocol at the discretion of the Investigator
Prior/concomitant therapy
- Active antibiotic use
- Active treatment with high levels of immunosuppressive therapies (active chemotherapy or immunosuppressive medications [including steroids, biologic therapy, or bone marrow suppressive agent], or radiation therapy)
- Simultaneous participation in another interventional clinical trial
Other exclusion criteria
-Inability to comply with research requirements
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Healthy Donors
This group consists of healthy stool donors.
|
This is an observational study with no interventions.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Donor Eligibility Rate
Délai: During screening period
|
Proportion of screened individuals who meet eligibility criteria for stool donation
|
During screening period
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Microbiome Diversity of Donors
Délai: Baseline and every 60 days through study completion, up to 12 months
|
Alpha diversity (e.g., Shannon index) of stool samples from eligible donors
|
Baseline and every 60 days through study completion, up to 12 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Sean Spencer, MD, PhD, Stanford University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- IRB 85544
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .